Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap With Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Ren et al., 2024
Rosnilimab, a PD-1 Agonist Antibody in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis
Parmley et al., 2024
Imsidolimab, an IL-36 Receptor Antagonist, Was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients With Generalized Pustular Psoriasis Results From the Phase 3 Trials, GEMINI-1 and GEMINI-2
Reich et al., 2024
Atopic Dermatitis is Characterized by Enrichment in a BTLA Transcriptomic Signature
Ren et al., 2024
ANB032, a BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Muench et al., 2024
ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Soroosh et al., 2024
ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease
Hare et al., 2024
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
ANB032, a BTLA (B and T Cell Lymphocyte Attenuator) Checkpoint Receptor Agonist, Modulates Dendritic Cell Maturation and Function
Soroosh et al., 2024
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model
Hare et al., 2024
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model
Hare et al., 2024
ANB032, an Investigational B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Muench et al., 2024